Clinical Trials Sponsored by Harpoon Therapeutics

Total 6333 results

Amicus Therapeutics

Completed

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Fabry Disease

United States
Wellstat Therapeutics

Completed

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Hereditary Orotic Aciduria

United States
Celldex Therapeutics

Completed

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

Advanced Cancer

United States
Corcept Therapeutics

Terminated

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Psychosis | Psychotic Depression | Severe Major Depression With Psychotic Features

United States
Noven Therapeutics

Completed

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

ADHD

United States
Noven Therapeutics

Completed

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

ADHD

United States
Noven Therapeutics

Completed

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

Attention Deficit Hyperactivity Disorder

United States
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
Osiris Therapeutics

Terminated

TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers

Diabetic Foot Ulcers

United States
Acorda Therapeutics

Completed

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

Epilepsy

United States
Aerpio Therapeutics

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

IBD

Canada
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Acorda Therapeutics

Completed

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

Parkinson's Disease

United States
Argos Therapeutics

Completed

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Kidney Cancer | Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States
Cytori Therapeutics

Completed

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee (ACT-OA Knee)

Osteoarthritis, Knee

United States
UVLrx Therapeutics

Completed

Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline

Quality of Life | Fatigue

United States
Lumen Therapeutics

Terminated

PolyArginine Treated vEiN grafTs (PATENT)

Saphenous Vein Graft Disease

Canada
Acorda Therapeutics

Completed

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Smoking

United States
Intarcia Therapeutics

Completed

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

Renal Insufficiency

Germany, United States
BIND Therapeutics

Completed

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Russian Federation
Intarcia Therapeutics

Completed

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

Healthy Adult Premenopausal Female Volunteers

United States
Wellstat Therapeutics

Approved for marketing

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Toxicity Due to Chemotherapy
United Therapeutics

Terminated

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Australia
Centrexion Therapeutics

Terminated

Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

Acute-onset Herpes Zoster Pain

Australia
Chelsea Therapeutics

Terminated

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

Parkinson's Disease | Pure Autonomic Failure | Dopamine Beta Hydroxylase Deficiency | Symptomatic Neurogenic Orthostatic Hypotension | Multiple Systems Atrophy

United States
Resolve Therapeutics

Completed

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
Noven Therapeutics

Completed

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Hot Flashes

United States
Noven Therapeutics

Completed

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Hot Flashes

United States
United Therapeutics

Completed

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Neuroblastoma

United States
Heron Therapeutics

Completed

A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin

Healthy

United States
Intarcia Therapeutics

Completed

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Breast Neoplasms | Neoplasms, Hormone-dependent

United States, Canada, Russian Federation, Ukraine
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Androgen-independent Prostate Cancer

United Kingdom
Io Therapeutics

Completed

Study of IRX4204 for Treatment of Early Parkinson's Disease

Parkinson's Disease

United States
Intarcia Therapeutics

Completed

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Sangamo Therapeutics

Completed

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

HIV Infections | HIV Infection

United States
vTv Therapeutics

Completed

A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Mateon Therapeutics

Completed

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer (FALCON)

Tumors

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
United Therapeutics

Withdrawn

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

PAH

United States
Halozyme Therapeutics

Completed

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Diabetes Mellitus

United States
Acorda Therapeutics

Completed

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure (GGF2-1101-1)

Heart Failure

United States
Corcept Therapeutics

Terminated

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Cushing's Syndrome

United States
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Gastroesophageal Reflux Disease (GERD)

United States
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Pouchitis

United States
Corcept Therapeutics

Completed

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Cushing's Syndrome

United States
Intarcia Therapeutics

Terminated

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

Breast Cancer

United States
United Therapeutics

Terminated

Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)

Systemic Sclerosis

United States, Canada, United Kingdom
Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel

3

Subscribe